<< Back to News

System Formulary Update
Extended-Spectrum Beta-Lactams

Situation

The Extended-Spectrum Beta-Lactam class review and formulary standardization was approved at the July 2021 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: cefiderocol (Fetroja), ceftazidime-avibactam (Avycaz), ceftolozane-tazobactam (Zerbaxa), imipenem-cilastatin-relebactam (Recarbrio), meropenem-vaborbactam (Vabomere)

Assessment/Recommendations

Changes Effective: Tuesday, August 31, 2021

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Cefiderocol: 1 g vial
• Ceftazidime-avibactam: 5 g vial
• Ceftolozane-tazobactam: 1.5 g vial
• Imipenem-cilastatin-relebactam: 25 g vial
• Meropenem-vaborbactam: 2 g vial

As a result, the following products will be removed from the inpatient drug formulary:

• None